Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 30;10(7):1652. doi: 10.3390/cells10071652

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Figure A6 — IL1β analysis after 3 h pre-treatment with Nigericin or LPS followed by 6 h stimulation with PHF6/aPHF6. The treatment with unaggregated PHF6 or aggregated aPHF6 lead to no secretion of IL1β. LPS was used as a positive control, which also lead to no secretion. For NLRP3 priming, cells were pre-treated with Nigericin or LPS for 3 h followed by PHF6 or aPHF6 treatment for 6 h. Only the combination of Nigericin and LPS stimulation increased the IL1β secretion into the supernatant. Only minor levels were found after Nigericin only, and in combination with aPHF6 or PHF6. Similar levels were found after LPS pre-treatment as a priming agent.